Author Correction: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer

Nat Commun. 2023 Dec 14;14(1):8321. doi: 10.1038/s41467-023-44124-y.

Paolo Tarantino^#^{1

2

3

4}, Hersh Gupta^#^{5

6}, Melissa E Hughes⁵, Janet Files⁵, Sarah Strauss⁵, Gregory Kirkner⁵, Anne-Marie Feeney⁵, Yvonne Li⁵, Ana C Garrido-Castro^{5

7

8}, Romualdo Barroso-Sousa^{9

10}, Brittany L Bychkovsky^{7

8

11}, Simona DiLascio⁵, Lynette Sholl⁵, Laura MacConaill⁵, Neal Lindeman^{5

12}, Bruce E Johnson⁵, Matthew Meyerson^{5

8

6}, Rinath Jeselsohn^{5

7

8}, Xintao Qiu⁵, Rong Li⁵, Henry Long⁵, Eric P Winer¹³, Deborah Dillon^{8

14}, Giuseppe Curigliano¹⁵, Andrew D Cherniack^{5

8

6}, Sara M Tolaney^{5

7

8}, Nancy U Lin^{5

7

8}

¹ Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. [email protected].
² Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA. [email protected].
³ Harvard Medical School, Boston, MA, USA. [email protected].
⁴ Department of Oncology and Hematology-Oncology, University of Milano, Milano, Italy. [email protected].
⁵ Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
⁶ Broad Institute of Harvard and MIT, Cambridge, MA, USA.
⁷ Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
⁸ Harvard Medical School, Boston, MA, USA.
⁹ Dasa Institute for Education and Research (IEPD), Brasilia, Brazil.
¹⁰ Dasa Oncology/Hospital Brasilia, Brasilia, Brazil.
¹¹ Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute, Boston, MA, USA.
¹² Department of Pathology, Weill Cornell Medicine, New York, NY, USA.
¹³ Yale Cancer Center, Yale School of Medicine, Smilow Cancer Hospital, New Haven, CT, USA.
¹⁴ Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
¹⁵ Division of Early Drug Development, European Institute of Oncology IRCCS, Milano, Italy.

^# Contributed equally.

No abstract available

Publication types